Research & Publications
One of the major treatment tools for breast cancer is antiestrogen treatment against estrogen Receptor-alpha (ERa) and it is the accepted therapeutic prognostic marker to predict the response of an individual breast cancer to antiestrogen therapy. However, approximately 50% of ERa positive breast cancers are de novo resistant to selective estrogen receptor modulators (SERMs) and many breast cancers acquire tamoxifen (Tam) resistance during progression due to de novo and acquired resistance to tamoxifen and seriously limit the efficacy of this treatment. The reasons for this lack of response are poorly understood. One of the mechanisms may be related to the second receptor ER-beta. I am pursuing the receptor to determine a possible targeted therapy for breast cancer.
Specialized Terms: Immunopathology; Molecular Pathology; Cytopathology and Clinical Pathology; Breast Cancer;
Extensive Research Description
Breast Neoplasms; Pathology; Medical Laboratory Science; Selective Estrogen Receptor Modulators; Estrogen Receptor alpha
- Evidence-based medical practice and the outcomes of education.ChoiY, Krause L. Evidence-based medical practice and the outcomes of education. Modern Pathol 2011; 24:129A
- ERß1, AIB-1 and TIF-2 expression in breast cancer-associated myofibroblasts.Choi Y. ERß1, AIB-1 and TIF-2 expression in breast cancer-associated myofibroblasts. Modern Pathol 2010; 23:40A.
- Tissue –specific expression of estrogen receptor-ß wild type and its isoforms.Choi Y. Tissue –specific expression of estrogen receptor-ß wild type and its isoforms. Arch Pathol Lab Med 2009; 133:1632.
- Co-expression of ER-alpha and beta and over-expression of ER-beta in recurrent and metastatic breast cancer.Choi Y. Co-expression of ER-alpha and beta and over-expression of ER-beta in recurrent and metastatic breast cancer. Lab Investigation 2004 84:26A.
- Diets and growth factors in breast cancer.Choi Y. Diets and growth factors in breast cancer. J of KAMA 2003, 9:27-34